ACXP Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Acurx Pharmaceuticals Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerACXP

Market Cap8.2M

Cash RunwayRunway > 12 months

Next Catalyst2027-09-29

Public Research Snapshot

Acurx Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Ibezapolstat in Clostridium Difficile Infection (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Stock Information	n/a	n/a	Preclinical	Public pipeline row
Ibezapolstat	Clostridium Difficile Infection	n/a	Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2027-09-29	Ibezapolstat	Low
Presentation	October 2025	n/a	Low
Data Readout	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT04247542	Phase 2	COMPLETED	53	2023-10-03
NCT07513285	Phase 2	NOT_YET_RECRUITING	20	2027-09-29

Scientific Context

catalyst_type | Presentation
catalyst_type | Data Readout
catalyst_window | October 2025
asset_name | Ibezapolstat
catalyst_date_estimated | 2027-09-29

Want the full ACXP research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.